Presence and amount of gut bacteria can predict how fast pancreatic cancer cells grow
(Natural News) Pancreatic ductal adenocarcinoma, or PDA, is the most common and by far the most lethal form of pancreatic cancer. Pancreapedia reports that it is extremely aggressive, and for most patients their only hope of survival hinges on the total surgical removal of the tumor. Unfortunately, such tumors cannot be removed in upwards of...
ConclusionsThere have been significant improvements in pancreatic cancer care over the last decade, as evidenced by earlier diagnosis, increased utilization of surgery, and improvement in overall survival for both resected and un-resected patients.
Pancreatic ductal adenocarcinoma (PDAC) constitutes one of the most challenging lethal tumors and has a very poor prognosis. In addition to cancer cells, the tumor microenvironment created by a repertoire of resident and recruited cells and the extracellular matrix also contribute to the acquisition of hallmarks of cancer. Among these factors, cancer-associated fibroblasts (CAFs) are critical components of the tumor microenvironment. CAFs originate from the activation of resident fibroblasts and pancreatic stellate cells, the differentiation of bone marrow-derived mesenchymal stem cells and epithelial-to-mesenchymal transi...
Conditions: Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC); Pancreatic Ductal Adenocarcinoma Interventions: Radiation: Stereotactic Body Radiation (SBRT); Drug: Nivolumab; Drug: CCR2/CCR5 dual antagonist; Drug: GVAX Sponsors: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Bristol-Myers Squibb Not yet recruiting
ConclusionsThe addition of the botanical formula LCS101 to irradiated cancer cells results in an apparent additive effect, most likely through a ROS-mediated mechanism. These findings support the use of LCS101 by patients undergoing radiation therapy, for both its clinical as well as anti-cancer effects.
Potential four‑miRNA signature associated with T stage and prognosis of patients with pancreatic ductal adenocarcinoma identified by co‑expression analysis. Mol Med Rep. 2018 Nov 19;: Authors: You L, Wang J, Zhang F, Zhang J, Tao H, Zheng X, Hu Y Abstract With a 5‑year survival rate of only 8%, pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer‑associated mortality worldwide. Unfortunately, even following radical surgery, patient outcomes remain poor. Emerging as a new class of biomarkers in human cancer, microRNAs (miRNAs/miRs) have been reported to have various...
Condition: Pancreas Cancer Interventions: Drug: Entinostat; Drug: FOLFOX regimen Sponsors: Abramson Cancer Center of the University of Pennsylvania; Syndax Pharmaceuticals, Inc. Not yet recruiting
ConclusionLess than 50% of IAR regularly participate in a proposed PDAC screening program, although the associated psychological burden is quite low. Physicians should be educated about high risk PDAC groups and screening recommendations. Time and travel efforts must be reduced to encourage more IAR to participate in a recommended screening.
CONCLUSIONS: Our results suggested that polymorphisms of these two lncRNA polymorphisms implicated in pancreatic carcinogenesis. Further large-scale and functional studies are needed to confirm our results. PMID: 30475759 [PubMed - as supplied by publisher]